The FDA granted Breakthrough Therapy designation to INCA033989 for the treatment of patients with ET harboring a Type 1 CALR mutation who are resistant or intolerant to at least one cytoreductive ...
The last time I spoke about Tectonic Therapeutic, Inc. (TECX), it was in a Seeking Alpha article entitled "Tectonic: Expansion OF TX45 Candidate Possible After Positive Interim Data." In the article, ...
The last time I wrote about IDEAYA Biosciences (IDYA), it was with respect to a Seeking Alpha article entitled "Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849." With respect to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback